Progenics develops innovative medicines and other technologies to target and treat cancer. Progenicsâ pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA, PSMA TTC and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLâ˘), and 3) imaging analysis technology. Progenics has two commercial products, RELISTORÂŽ (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
Source
